International ClinicsMedical News
International Clinics Newsroom · · 1 min read
Daily

FDA grants accelerated approval to neladalkib for ALK-positive lung cancer

  • On 17 November 2026 the FDA granted accelerated approval to Nelkarmi (neladalkib).
  • It treats advanced ALK-positive non-small cell lung cancer after earlier targeted therapy.
  • Approval is based on the ALKOVE-1 trial of 222 patients.
  • Response rates were 49% in one cohort and 32% in a more heavily pretreated cohort.
FDA building with the neladalkib approval announcement
FDA building with the neladalkib approval announcement Photo: OncoDaily
Published:

The FDA granted accelerated approval to Nelkarmi (neladalkib) on 17 November 2026 for locally advanced or metastatic ALK-positive non-small cell lung cancer that has progressed after earlier targeted therapy.

Trial results

Approval is based on ALKOVE-1, which enrolled 222 patients. The overall response rate was 49% in a cohort of 67 patients and 32% in a cohort of 155 more heavily pretreated patients. Intracranial responses were 55% and 26%, which matters because this cancer often spreads to the brain.

What accelerated approval means

Accelerated approval relies on early measures such as response rate; continued approval depends on confirmatory trials. The dose is 150 mg once daily, and raised liver enzymes are among the main side effects, so liver tests are monitored.

Sources: FDA — Novel Drug Approvals 2026, OncoDaily

This story is relayed from the source named above; responsibility for its content rests with the original source.

FAQ

What is neladalkib (Nelkarmi)?

Neladalkib is an oral targeted drug for ALK-positive non-small cell lung cancer that received FDA accelerated approval on 17 November 2026.

Who can use neladalkib?

Neladalkib is for patients with advanced ALK-positive lung cancer that progressed after earlier targeted therapy.

What did ALKOVE-1 show?

In ALKOVE-1 (222 patients), neladalkib produced a 49% response rate in a 67-patient cohort and 32% in a 155-patient, more pretreated cohort.

Does neladalkib work on brain metastases?

Yes. Neladalkib produced intracranial responses of 55% and 26% in the two ALKOVE-1 cohorts.

What does accelerated approval of neladalkib mean?

Neladalkib's accelerated approval rests on response rates; continued approval depends on confirming clinical benefit in later trials.

How would you rate this story?
149
Latest news
A fluoride-free gel that may rebuild tooth enamel, from the University of Nottingham Jackson 5's Marlon Jackson reveals he has lived with prostate cancer for four years Tip of the day: get your flu vaccine early, before winter peaks Every plant-based food in a UK study contained fungal toxins, all within EU guideline levels Tip of the day: spit, don't rinse, after brushing your teeth Energy drinks appear 11 times more often in cardiac arrest reports, preliminary study finds ISAPS global survey: eyelid surgery leads, breast lift grows fastest and filler declines Hippocrates: "Life is short, and Art long" Born on this day: William Beaumont and the hole in a stomach that rewrote digestion Tip of the day: sleep at least 7 hours a night, on a regular schedule
The latest-news bar is closed. You can bring it back any time with the “Latest news” button in the menu.